Related Experiment Video
Updated: Jun 24, 2026

Establishment of a Mouse Severe Acute Pancreatitis Model using Retrograde Injection of Sodium Taurocholate into the Biliopancreatic Duct
Published on: April 1, 2022
Exenatide and acute pancreatitis.
N R Tripathy1, S Basha, R Jain
1Dr. A. Ramachandran's Diabetes Hospitals, Chennai 600 008, India.
A patient taking Exenatide (Byetta) for type 2 diabetes experienced acute pancreatitis. The drug was stopped, and the patient recovered, highlighting a potential risk associated with this medication.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes management often requires combination therapy.
- Exenatide (Byetta) is a glucagon-like peptide-1 receptor agonist used for glycemic control.
Observation:
- A female patient with a 4-year history of type 2 diabetes was prescribed Exenatide alongside Glimepiride and Metformin.
- Gastrointestinal disturbances began on the first day of Exenatide injection.
- Acute pancreatitis symptoms emerged by the eighth day, confirmed by CT scan and labs.
Findings:
- Exenatide (Byetta) administration was associated with the development of acute pancreatitis in a type 2 diabetic patient.
- Withdrawal of Exenatide led to the resolution of pancreatitis symptoms.
Implications:
- Clinicians should be vigilant for pancreatitis symptoms in patients treated with Exenatide.
- This case underscores the importance of monitoring for adverse drug reactions, particularly gastrointestinal and pancreatic events, with GLP-1 receptor agonists.
Related Concept Videos
Acute Pancreatitis I: Introduction
Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Acute Pancreatitis II: Clinical Manifestations and Management
Acute Pancreatitis II: Pathophysiology
Dipeptidyl Peptidase 4 Inhibitors

